Key facts
- It has raised $2.0M; the latest was Angel (individual) in Dec 2025.
- Notable investors include Ashish Kacholia, Centre for Cellular And Molecular Platforms, Manish Gandhi, Tenshi Pharmaceuticals.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Sekkei Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Sekkei Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sekkei Bio
Operator of an innovation-driven biopharmaceutical company intended to develop next-generation medicines that address global unmet healthcare needs and improve human health. The company offers cutting-edge drug discovery platforms that integrate deep science, physics, and machine learning to design multi-targeted drugs and RNA-based therapeutics, enabling customers to access novel, inclusive, and cost-effective healthcare services such as oral insulin delivery, thermostable insulin for easier supply chains, and non-opioid analgesics for safer pain management.
- Sector
- Healthcare
- HQ
- Chennai, India
- Founded
- 2017
- Employees
- 20
- Website
- sekkeibio.com/
- Ownership
- Privately Held (backing)
Sekkei Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sekkei Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sekkei Bio in its N-PORT filings yet. We sweep new filings monthly.